2019 ASCO Annual Meeting!
Session: Cancer Prevention, Hereditary Genetics, and Epidemiology
Type: Poster Session
Time: Monday June 3, 1:15 PM to 4:15 PM
Location: Hall A
A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status.
Cancer Prevention, Hereditary Genetics, and Epidemiology
2019 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #57)
J Clin Oncol 37, 2019 (suppl; abstr 1563)
Author(s): Kimmie McLaurin, Tapashi Dalvi, Jenna M Collins, Beth L Nordstrom, Susan McCutcheon, James C Bennett, Brian R Murphy, Puneet K Singhal, Josefa Maria Briceno; AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD; Evidera, Waltham, MA; AstraZeneca, Cambridge, United Kingdom; Merck, North Wales, PA
Background: Limited data exist on the real-world treatment patterns and effectiveness of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors in the germline BRCA (gBRCA) mutated breast cancer population. Methods: Adults with human epidermal growth factor receptor 2 negative (HER2-), hormone receptor positive (HR+) metastatic breast cancer (mBC) treated with a CDK4/6 inhibitor from 01Jan2013–31Jan2018 were retrospectively selected from the Flatiron Health Oncology electronic medical record database. Patients with known gBRCA status were classified as having gBRCA mutated (gBRCAm) or wild type (gBRCAwt) disease. Time to first subsequent therapy or death (TFST) and overall survival (OS) were calculated from start of the earliest line of therapy with a CDK4/6 inhibitor. Kaplan-Meier (KM) medians were estimated, and TFST and OS compared between gBRCA groups with Cox models stratified by line of therapy and adjusting for demographic and clinical characteristics that modified hazard ratios (HRs) for gBRCA status by > 10%. Results: Of 2968 HER2- HR+ patients with mBC receiving a CDK4/6 inhibitor, gBRCA status was known for 859 (28.9%). Patients with gBRCAm and gBRCAwt received letrozole plus palbociclib (42.4 and 39.8%, respectively), fulvestrant plus palbociclib (32.9 and 30.7%), or other CDK4/6 regimens (24.7 and 29.5%) across all lines. The gBRCAm group had a non-significant, shorter TFST than gBRCAwt (stratified HR 1.24; 95% CI 0.96–1.59). OS was significantly shorter in gBRCAm than gBRCAwt patients (stratified HR 1.50; 95% CI 1.06–2.14). Conclusions: The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be poorer in patients with gBRCAm compared with gBRCAwt disease. These findings indicate a higher unmet need among patients with gBRCAm, potentially requiring alternative treatment options.
|Characteristic or Outcome||gBRCAm |
(N = 85; 9.9%)
|gBRCAwt (N = 774; 90.1%)|
|Mean (SD) age, years||53 (13.4)||58 (12.0)|
|Line of earliest CDK4/6 use|
|TFST, months*||11 (6–18)||14 (12–15)|
|TFST, months*||10 (6–11)||10 (8–12)|
|Third and higher, %||25.9||29.5|
|TFST, months*||6 (3–11)||7 (5–9)|
*Data are KM median (95% confidence interval [CI])
1. Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.